Shifting the paradigm for autism treatments
نویسندگان
چکیده
منابع مشابه
Shifting the Parallel Programming Paradigm
Multicore computer architectures are now the standard for desktop computers, high-end servers and personal laptops. Due to the multicore shift in computer architecture, software engineers must write multithreaded programs to harness the resources of these parallel machines. Unfortunately, today’s parallel programming techniques are difficult to reason about, highly error-prone and challenging t...
متن کاملParadigm Shift or Shifting Paradigm for Type 1 Diabetes
The age of onset of type 1A diabetes is now immunologically predictable (1). Either because of a lack of sufficient understanding of the pathogenesis of type 1A (immune-mediated) diabetes or a lack of effective therapeutics directed at relevant pathogenic pathways (or both), we cannot yet prevent this disease (2). The article by Liu et al. (3) in this issue of Diabetes addresses both issues in ...
متن کاملThe most effective treatments for autism
Since the discovery of autism major gains have been accomplished in helping others understand what it is and helping those who are diagnosed. While there is no cure for autism there are a variety of treatments that are used today. Defined as a having “difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors.”(Autism Speaks 2014) It seems that autism begins...
متن کاملShifting the Paradigm in Hemolytic Uremic Syndrome.
In this issue of the journal, Ardissino et al1 report that early volume expansion in children with hemolytic uremic syndrome associated with Shiga toxinproducing Escherichia coli (STECHUS) significantly improves clinical outcomes. The observation possesses significant clinical implications for the management of an illness that causes much morbidity and not infrequently, mortality.2 The data are...
متن کاملPalliative care--a shifting paradigm.
n engl j med 363;8 nejm.org august 19, 2010 781 Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates 4. with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53. Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III 5. multi-institutional randomized study of immunization with the gp100:209-217(210M)...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurotherapeutics
سال: 2010
ISSN: 1933-7213,1878-7479
DOI: 10.1016/j.nurt.2010.05.010